Bryan Johnson Spent an Hour With His Clinical Team Debating This GH Peptide Decision. Here's What the Evidence Says — And What Australian Practitioners Would Prescribe.

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. Information on this site does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

This article is written in response to Bryan Johnson's publicly shared post at x.com/bryan_johnson. Johnson has not endorsed ProtocolHub or reviewed this content.

Bryan Johnson — who has reversed his biological age by 5.1 years and tracks more biomarkers than most hospitals — spent over an hour with his clinical team unable to agree on which growth hormone peptide protocol to run. He posted the entire debate publicly. Both options he described are legally accessible in Australia via AHPRA prescription and compounding pharmacy right now. Here is what the published evidence says about each one, whether his stacking hypothesis with tirzepatide holds up to scrutiny, and the practical answer most Australian practitioners would give him.

What Bryan Johnson is actually debating — the two candidates

Johnson framed the decision clearly. Two protocols, both targeting the same outcome — increased GH and IGF-1 to support anabolism, recovery, and sleep — with meaningfully different pharmacokinetics, evidence bases, and practical tradeoffs.

Option 1: CJC-1295 with DAC — the long-acting version

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC component binds the peptide to circulating albumin, extending its half-life from roughly 30 minutes to 5.8–8.1 days. One injection per week maintains active GH and IGF-1 stimulation throughout.

Johnson's characterisation of the clinical data is accurate. The pivotal human trial — Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006 — was two randomised, placebo-controlled, double-blind dose trials in healthy adults. Results: a single subcutaneous injection of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations of 2–10 fold for six days or more, and mean plasma IGF-1 concentrations of 1.5–3 fold for nine to eleven days. Multiple doses produced IGF-1 levels sustained at 1.5–3 times baseline for up to 28 days. The half-life ranged from 5.8 to 8.1 days. This is genuine published RCT data.

The doses Johnson is considering — 2.4 mg starting, escalating to 4.8 mg weekly — are directly within the trial range. The published protocol used 30–60 μg/kg subcutaneously; for an 80 kg individual, that is 2.4–4.8 mg per week.

The tradeoff Johnson names is real: if side effects occur — joint stiffness, water retention, or changes in glucose handling — you are committed to that dose for nearly a week. You cannot titrate day-by-day.

Option 2: CJC-1295 without DAC + Ipamorelin — the short-acting combination

CJC-1295 without DAC (also called Modified GRF 1-29) is the same GHRH analogue stripped of the albumin-binding component. Its half-life is approximately 30 minutes. It is administered daily, typically before bed to align with the body's natural GH release peak during slow-wave sleep.

Ipamorelin is a separate mechanism entirely — a synthetic pentapeptide that activates the ghrelin receptor (GHS-R), creating a second pathway for GH release that acts on pulse frequency rather than amplitude. Johnson correctly notes it produces no elevation in cortisol or prolactin. This is one of ipamorelin's most important clinical characteristics: it was established in the 1998 founding pharmacology paper by Raun et al. published in the European Journal of Endocrinology. At doses up to 1 mg/kg intravenously, ipamorelin elevated only GH — it did not affect ACTH, cortisol, prolactin, or any other pituitary hormone. This selectivity is the defining advantage over older GH secretagogues like GHRP-6, which raise cortisol and prolactin significantly.

The combination produces what practitioners describe as a dual-axis GH pulse: CJC-1295 without DAC amplifies GH release amplitude via the GHRH pathway, while ipamorelin increases pulse frequency via the ghrelin pathway. Together they mimic natural GH pulsatility more closely than either compound alone.

The tradeoff Johnson names is also accurate: there is significantly less published clinical trial data for this combination than for CJC-1295 with DAC. The evidence base is largely mechanistic reasoning, practitioner case series, and the extensive real-world use Johnson references.

The stacking hypothesis — does it hold up?

The most analytically interesting part of Johnson's post is his hypothesis about combining either CJC-1295 variant with tirzepatide, betting that the two compounds' side effect profiles cancel each other out. This is worth examining carefully because it is a hypothesis, not established science — and Johnson is explicit that he is testing it.

The insulin resistance claim. Johnson states that CJC-1295 can worsen insulin resistance while tirzepatide counteracts it. Both halves are mechanistically correct. Growth hormone is a counter-regulatory hormone — it reduces glucose uptake in peripheral tissues, which raises insulin resistance. GHRH analogues like CJC-1295 elevate GH, so this concern is pharmacologically grounded. Tirzepatide (dual GIP/GLP-1 agonist) improves insulin sensitivity through multiple pathways. The logic of the two opposing effects is sound. What is unknown is whether tirzepatide fully offsets CJC-1295-induced insulin resistance at any given dose combination. No published trial has tested this specific pairing.

The sleep disruption claim. Tirzepatide disrupts sleep in some patients — elevated resting heart rate and altered gastric motility are the primary drivers. GHRH is a well-established promoter of slow-wave sleep in the neuroendocrinology literature. CJC-1295, as a GHRH analogue, could theoretically support SWS. The biological logic holds. Whether the effect magnitude is sufficient to offset tirzepatide's disruption is unknown without the tracking Johnson proposes — HRV, rMSSD, and sleep architecture measurement.

The RHR claim. Johnson notes tirzepatide can elevate resting heart rate. He does not claim CJC-1295 counteracts this — and it is worth stating explicitly that GH secretagogues do not meaningfully affect RHR in either direction. The RHR elevation from tirzepatide's glucagon-like peptide mechanism is not offset by adding CJC-1295. Anyone running this combination should monitor RHR independently.

The overall verdict on the hypothesis: Two of the three proposed counterbalancing mechanisms are mechanistically plausible and worth testing with the biomarker panel Johnson describes. The RHR point is a residual risk that should be monitored rather than assumed resolved. The honest framing — "best of both worlds, or at least, that's the hypothesis we're testing" — is appropriate.

Find an Australian prescriber experienced with GH secretagogue protocols →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

What the evidence says — and what Australian practitioners would prescribe

Johnson frames the decision as purist versus pragmatist. The clinical trial purist goes with DAC. The pragmatist goes with no-DAC plus ipamorelin because that is what the real-world user base actually runs.

There is a third frame that is more useful for most people: risk tolerance and titration preference.

If you are starting for the first time, or if medical supervision is limited: CJC-1295 without DAC plus ipamorelin is the right starting point. The one-week commitment of the DAC version is a meaningful practical risk for anyone who has not established their individual response to GH secretagogues. Australian practitioners overwhelmingly prescribe the no-DAC plus ipamorelin combination as the initial protocol precisely because of the titration advantage. If you experience joint pain, water retention, or blood sugar changes, you stop for 24 hours and adjust. With DAC, you wait a week.

If your baseline blood work supports it and you are comfortable with the commitment: CJC-1295 with DAC at 2.4 mg weekly (Johnson's starting dose) is clinically rational. The published data is genuinely stronger. The weekly convenience is meaningful. And for someone with Johnson's level of biomarker monitoring — CGM, daily HRV, IGF-1 testing — the week-long commitment is less concerning because the signal is fast.

On the head-to-head comparison Johnson proposes: This is actually the most scientifically valuable option and the one ProtocolHub would endorse for anyone with access to regular blood work. Two weeks of DAC followed by two weeks of no-DAC plus ipamorelin, with IGF-1, GH, HOMA-IR, and sleep architecture measured at the end of each phase, generates personally calibrated data. Johnson is right that this produces "more socially relevant data" — it is also the most individually useful approach.

Australian access — both options, what they cost

Both protocols are Schedule 4 in Australia. They require a prescription from an AHPRA-registered practitioner and must be sourced through a TGA-licensed compounding pharmacy. Neither is PBS-listed.

CJC-1295 with DAC (weekly injection) Access via AHPRA telehealth consultation and licensed compounding pharmacy. Typical starting dose 2.4 mg weekly. Monthly cost: $180–$280 AUD/month at current Australian compounding rates.

CJC-1295 without DAC + Ipamorelin (daily pre-bed) The most commonly prescribed GH secretagogue combination in Australian peptide clinics. Typical starting dose: 100 mcg of each, pre-bed, titrating to 200–300 mcg over 4–8 weeks. Monthly cost: $150–$250 AUD/month depending on clinic and compounding pharmacy.

The no-DAC plus ipamorelin combination is on ProtocolHub's platform as the Ipamorelin + CJC-1295 protocol, and it features in the Outlive Longevity Protocol and the Neuroscience Performance Protocol.

What Bryan's biomarker tracking teaches the rest of us

The most valuable part of Johnson's post is not which protocol he chooses — it is the measurement framework he outlines. His tracking panel: GH, IGF-1, cortisol, CGM, real-time core body temperature, RHR, overnight HRV (rMSSD), HOMA-IR, sleep architecture, and subjective recovery.

Most people running GH secretagogues in Australia track none of this. They inject the peptide, notice they feel better or worse, and continue or stop. Johnson's framework is what actually generates signal: you cannot optimise a protocol you are not measuring.

The minimum viable biomarker panel for any Australian starting CJC-1295 or ipamorelin:

• Baseline IGF-1 — the primary efficacy marker; test before starting and at 4 weeks
• Fasting glucose + insulin (HOMA-IR) — the insulin resistance signal Johnson is monitoring; particularly important if stacking with tirzepatide
• Resting heart rate — trackable via wearable; if running tirzepatide concurrently, monitor daily
• Subjective sleep quality — Oura Ring, Whoop, or the Apple Watch sleep score gives consistent, comparable data

A clinic that includes baseline blood work in its intake process — not just a prescription and a send-off — is the appropriate setting for this protocol. Thrive Rx's blood-panel-first model is the closest match on ProtocolHub to what Johnson's framework demands.

---

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. Information on this site does not constitute medical advice.

What to read next

• Ipamorelin + CJC-1295 peptide profile — full Australian access guide and evidence summary
• The Outlive Longevity Protocol — Peter Attia's biomarker-first framework, which includes the GH secretagogue layer
• The Neuroscience Performance Protocol — includes ipamorelin/CJC-1295 as the optional peptide layer
• Bryan Johnson's Blueprint Protocol — the Australian version — his full documented routine in an Australian context
• Longevity protocol guide — Australia — the comprehensive reference
• Compare Australian longevity clinics